Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bulleyaconitine a
- Development stage
- Phase 4
- Lead developer
- KPC Pharmaceuticals
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
Bulleyaconitine a is a C-19 diterpene diester alkaloid isolated from various *Aconitum* species, notably *Aconitum bulleyanum*. It is an analgesic and anti-inflammatory small molecule drug that acts primarily as a voltage-gated sodium channel blocker, reducing neuronal excitability and pain transmission. Clinically, it has been used in China since the 1980s for chronic pain associated with musculoskeletal disorders such as rheumatoid arthritis, frozen shoulder, muscle strain, and fracture-induced pain. Unlike opioids such as morphine, bulleyaconitine a is non-addictive. Its mechanism of action includes inhibition of voltage-gated sodium channels in dorsal root ganglion neurons and modulation of the Src/PI3K/Akt signaling pathway to inhibit osteoclast differentiation and bone destruction in conditions like rheumatoid arthritis. It also exhibits anesthetic activity when combined with other agents like lidocaine or epinephrine[1][2][3][4][6].
- Other names
- BulleyaconitineBULLEYACONITINE ABulleyaconi cine ABULLEYACONITINE A(P)Bulleyaconitine A-RMBULLEYACONITINE A(RG)crassicauline A(bulleyaconitine)Bulleyaconitine A USP/EP/BP
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)PIK3CA (Phosphoinositide 3-kinase alpha)SRC (Proto-oncogene tyrosine-protein kinase Src)SCN9A (Sodium channel protein type 9 subunit alpha)SCN10A (Sodium channel protein type X alpha subunit)
Beyond the preview
Go deeper on bulleyaconitine a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bulleyaconitine a.